Unknown

Dataset Information

0

Economic evaluation of betibeglogene autotemcel (Beti-cel) gene addition therapy in transfusion-dependent β-thalassemia.


ABSTRACT: Background: Standard of care (SoC) for transfusion-dependent β-thalassemia (TDT) requires lifelong, regular blood transfusions as well as chelation to reduce iron accumulation. Objective: This study investigates the cost-effectiveness of betibeglogene autotemcel ('beti-cel'; LentiGlobin for β-thalassemia) one-time, gene addition therapy compared to lifelong SoC for TDT. Study design: Microsimulation model simulated the lifetime course of TDT based on a causal sequence in which transfusion requirements determine tissue iron levels, which in turn determine risk of iron overload complications that increase mortality. Clinical trial data informed beti-cel clinical parameters; effects of SoC on iron levels came from real-world studies; iron overload complication rates and mortality were based on published literature. Setting: USA; commercial payer perspective Participants: TDT patients age 2-50 Interventions: Beti-cel is compared to SoC. Main outcome measure: Incremental cost-effectiveness ratio (ICER) utilizing quality-adjusted life-years (QALYs) Results: The model predicts beti-cel adds 3.8 discounted life years (LYs) or 6.9 QALYs versus SoC. Discounted lifetime costs were $2.28 M for beti-cel ($572,107 if excluding beti-cel cost) and $2.04 M for SoC, with a resulting ICER of $34,833 per QALY gained. Conclusion: Beti-cel is cost-effective for TDT patients compared to SoC. This is due to longer survival and cost offset of lifelong SoC.

SUBMITTER: Kansal AR 

PROVIDER: S-EPMC8205006 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Economic evaluation of betibeglogene autotemcel (Beti-cel) gene addition therapy in transfusion-dependent β-thalassemia.

Kansal Anuraag R AR   Reifsnider Odette S OS   Brand Sarah B SB   Hawkins Neil N   Coughlan Anna A   Li Shujun S   Cragin Lael L   Paramore Clark C   Dietz Andrew C AC   Caro J Jaime JJ  

Journal of market access & health policy 20210607 1


<b>Background</b>: Standard of care (SoC) for transfusion-dependent β-thalassemia (TDT) requires lifelong, regular blood transfusions as well as chelation to reduce iron accumulation. <b>Objective</b>: This study investigates the cost-effectiveness of betibeglogene autotemcel ('beti-cel'; LentiGlobin for β-thalassemia) one-time, gene addition therapy compared to lifelong SoC for TDT. <b>Study design</b>: Microsimulation model simulated the lifetime course of TDT based on a causal sequence in whi  ...[more]

Similar Datasets

| S-EPMC10644094 | biostudies-literature
| S-EPMC9461218 | biostudies-literature
| S-EPMC2680376 | biostudies-literature
| S-EPMC10460678 | biostudies-literature
| S-EPMC6613625 | biostudies-literature
| S-EPMC6057484 | biostudies-literature
| S-EPMC10786143 | biostudies-literature
| S-EPMC9608723 | biostudies-literature
| S-EPMC4476479 | biostudies-literature
| S-EPMC8409024 | biostudies-literature